The goals and objectives of the Career Development Program (CDP) are to provide training and guidancefor academic physician-scientists, clinician-investigators, and laboratory-based scientists who want todedicate their endeavors to leukemia translational research. To achieve these aims, the CDP will followthese objectives:1. Recruit and train physician, scientists, and senior postdoctoral fellows to become outstandingtranslational investigators in leukemia research;2. Mentor awardees in the latest advances in cancer biology, at both the molecular and cellular level,emphasizing the translational aspects of research;3. Provide environmental and institutional resources that enable the awardees to excel in their respectivefields of research as well as train them to be resourceful in the area of project development andscientific discovery;4. Foster professional growth in the area of translational research by encouraging awardees1 participationin seminars, presentations, conferences both within their parent institution and outside in the scientificcommunity.Lay Description: The goals and objectives of the Career Development Program (CDP) are to providetraining and guidance for academic physician-scientists, clinician-investigators, and laboratory-basedscientists who want to dedicate their endeavors to leukemia translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA100632-06
Application #
7468685
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Project Start
2008-05-01
Project End
2013-04-30
Budget Start
2008-09-01
Budget End
2009-04-30
Support Year
6
Fiscal Year
2008
Total Cost
$92,643
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Xia, Fang; Ning, Jing; Huang, Xuelin (2018) Empirical Comparison of the Breslow Estimator and the Kalbfleisch Prentice Estimator for Survival Functions. J Biom Biostat 9:
Trujillo-Ocampo, Abel; Cho, Hyun-Woo; Herrmann, Amanda C et al. (2018) Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy 20:1089-1101
Cortes, Jorge E; Tallman, Martin S; Schiller, Gary J et al. (2018) Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood 132:598-607
Ohanian, Maro; Rozovski, Uri; Kanagal-Shamanna, Rashmi et al. (2018) MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma :1-12
Boddu, P; Jorgensen, J; Kantarjian, H et al. (2018) Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia 32:241-244
Yan, Fangrong; Zhu, Huihong; Liu, Junlin et al. (2018) Design and inference for 3-stage bioequivalence testing with serial sampling data. Pharm Stat 17:458-476
Kelly, Andrew D; Madzo, Jozef; Madireddi, Priyanka et al. (2018) Demethylator phenotypes in acute myeloid leukemia. Leukemia 32:2178-2188
Levis, Mark J; Perl, Alexander E; Altman, Jessica K et al. (2018) A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv 2:825-831
Shah, Maitri Y; Ferracin, Manuela; Pileczki, Valentina et al. (2018) Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28:432-447
Masarova, Lucia; Verstovsek, Srdan; Hidalgo-Lopez, Juliana E et al. (2018) A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132:1664-1674

Showing the most recent 10 out of 487 publications